|
Myocardial Infarction
|
0.300 |
Biomarker
|
disease |
BEFREE |
Here we provide evidence for an independent, etiological role of PAI-1 in myocardial infarction.
|
7892190 |
1995 |
|
Myocardial Infarction
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Thus homozygosity for the 4G allele may predispose to elevated PAI-1 and impaired fibrinolysis, perhaps requiring interaction with other genetic or environmental factors to influence MI risk.
|
8571307 |
1995 |
|
Myocardial Infarction
|
0.300 |
Biomarker
|
disease |
BEFREE |
Before PAI-1 can be regarded as a risk factor in the conventional epidemiological sense, its relationship to myocardial infarction must be demonstrated in prospective studies of healthy populations.
|
8578529 |
1995 |
|
Myocardial Infarction
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
PAI-1 activity levels were also determined in the men who suffered a premature myocardial infarction 4 months after their discharge.
|
8883280 |
1996 |
|
Myocardial Infarction
|
0.300 |
Biomarker
|
disease |
BEFREE |
Does long-term angiotensin converting enzyme inhibition affect the concentration of tissue-type plasminogen activator-plasminogen activator inhibitor-1 in the blood of patients with a previous myocardial infarction.
|
9285181 |
1997 |
|
Myocardial Infarction
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Our data suggest that PAI-1 promoter polymorphism influences the development of myocardial infarction through its effect on thrombus formation in patients with preexisting coronary atheroma.
|
9012634 |
1997 |
|
Myocardial Infarction
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Elevated circulating levels of plasminogen activator inhibitor-1, the principle inactivator of the fibrinolytic system, have been related to the development of myocardial infarction.
|
9134651 |
1997 |
|
Myocardial Infarction
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
We assessed the 4G/5G polymorphism of the PAI-I gene in 500 subjects including 148 normal controls, 23 subjects with normal coronary arteries, 28 subjects with a paradoxical acetylcholine response, 97 subjects with angina pectoris (AP) and 204 subjects with myocardial infarction (MI).
|
9544737 |
1998 |
|
Myocardial Infarction
|
0.300 |
Biomarker
|
disease |
BEFREE |
Functional variants of angiotensin-1-converting enzyme (ACE), beta-fibrinogen, plasminogen activator inhibitor-1, methylenetetrahydrofolate reductase, glycoprotein Illa, and many apolipoprotein genes are considered excellent candidate risk factors for MI.
|
9649939 |
1998 |
|
Myocardial Infarction
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Sixty-six patients with myocardial infarction and sixty-two healthy control patients were chosen for the analysis of the PAI-1 promoter 4G/5G genotype with polymerase chain reaction-single strand conformation polymorphism.
|
9622220 |
1998 |
|
Myocardial Infarction
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
These results indicate that the G-->T mutation coding for factor XIIIVal34Leu is protective against myocardial infarction and suggest a mechanism whereby elevated levels of PAI-1 may contribute to vascular risk.
|
9459313 |
1998 |
|
Myocardial Infarction
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Plasminogen activator inhibitor-1 4G/5G-polymorphism and factor V Q506 mutation are not associated with myocardial infarction in young men.
|
9863707 |
1998 |
|
Myocardial Infarction
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Genetic control of PAI-1 expression has also been shown, involving a -675 4G/5G polymorphism, the 4G/4G genotype being associated with higher plasma PAI-1 levels; its proper influence on the development of myocardial infarction is still debated.
|
10980830 |
1999 |
|
Myocardial Infarction
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Lack of association of a common polymorphism of the plasminogen activator inhibitor-1 gene with coronary artery disease and myocardial infarction.
|
10577569 |
1999 |
|
Myocardial Infarction
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
In a multiple logistic regression analysis, age (OR 1.02 [95%-CI: 1.00-1.05]), total cholesterol (OR 1.40 [95%-CI: 1.14-1.71]), C-reactive protein levels >0.33 mg/l (OR: 1.87 [95%-CI: 1.10-3.20]), plasminogen activator inhibitor-1 4G/4G (OR: 1.84 [95%-CI: 1.27-2.66]), and MTHFR TT genotype (OR 1.62 [95%-CI: 1.08-2.42]), were all associated with a family history of myocardial infarction.
|
10456448 |
1999 |
|
Myocardial Infarction
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Increased plasma levels of coagulation proteins such as fibrinogen and plasminogen activator inhibitor-1 (PAI-1) are associated with an increased risk of myocardial infarction.
|
10554707 |
1999 |
|
Myocardial Infarction
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
In our study, the FXIII 34Leu allele was associated with a lower risk of MI (P = 0.009), however, the PAI-1 4G allele showed no interaction with this polymorphism.
|
10030380 |
1999 |
|
Myocardial Infarction
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Since 4G4G homozygotes of an insertion/deletion (4G/5G) gene variation in the promoter of PAI-I have been shown to have increased levels of PAI-I, we analysed the relation of this gene polymorphism to CAD and MI in a population of 2565 participants who underwent coronary angiography for diagnostic purposes.
|
10494775 |
1999 |
|
Myocardial Infarction
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
We investigated the distribution of this polymorphism in the "Study of Myocardial Infarctions Leiden" (SMILE), including 331 men with a myocardial infarction and 302 control subjects and measured PAI-1 antigen levels among the latter.
|
10456464 |
1999 |
|
Myocardial Infarction
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
To investigate the association between the risk of myocardial infarction at a young age and genetic factors thought to be associated with an increased tendency to thrombosis (the polymorphisms 4G/5G of the PAI-1 gene, PIA1/PIA2 of the platelet glycoprotein IIIa, C3550T of the platelet glycoprotein Ib gene, G10976A of the factor VII gene, C677T of the methylenetetrahydrofolate reductase gene, G1691A of the factor V gene, and G20210A of the prothrombin gene), we performed a case-control study evaluating 200 survivors (185 men, 15 women) of myocardial infarction who had experienced the event before the age of 45 years and 200 healthy subjects with a negative exercise test, individually matched for sex, age, and geographic origin with the cases.
|
10381497 |
1999 |
|
Myocardial Infarction
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Plasminogen activator inhibitor type-1 (PAI-1) is a major physiological inhibitor of fibrinolysis, with its plasma levels correlating with the risk for myocardial infarction and venous thrombosis.
|
10073956 |
1999 |
|
Myocardial Infarction
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
The PAI-1 4G/5G genotype was not associated with risk of myocardial infarction or other cardiovascular mortality.
|
10618306 |
2000 |
|
Myocardial Infarction
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
05), total cholesterol (OR 1.35, 95% CI 1.11 to 1.65), plasminogen activator inhibitor-1 4G/4G (OR 1.72, 95% CI 1.20 to 2.45), and CRP levels >0.33 mg/L (OR 1.75, 95% CI 1.05 to 2.91) were all independently associated with a positive family history of myocardial infarction.
|
10634818 |
2000 |
|
Myocardial Infarction
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism, coronary thrombosis, and myocardial infarction in middle-aged Finnish men who died suddenly.
|
10928474 |
2000 |
|
Myocardial Infarction
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
The insertion/deletion polymorphism (4G/5G) in the promotor region of the plasminogen activator inhibitor 1 (PAI-1) gene has been associated with an increased risk of myocardial infarction.
|
10971410 |
2000 |